InsiderTrades.com logo
Michelle LaSpaluto net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michelle LaSpaluto Biography and Net Worth

Chief Financial Officer of Chimerix

Michelle LaSpaluto joined Chimerix in 2011 and was named Chief Financial Officer in December 2023.

Prior to becoming CFO, Ms. LaSpaluto was Vice President of Corporate Financial Planning and Investor Relations since 2019. Since joining Chimerix in 2011 Ms. LaSpaluto has served in roles of increasing responsibility spanning finance, accounting, project planning, investor relations and strategy. She has over 25 years of experience in a range of financial, accounting and project planning roles. Prior to joining Chimerix, Ms. LaSpaluto was the senior director of accounting at AlphaVax, Inc. and started her career at Coopers & Lybrand in Detroit before transferring to Raleigh with PriceWaterhouseCoopers.

Ms. LaSpaluto received her MBA from East Carolina University and her B.A. in Accounting from Michigan State University.

What is Michelle LaSpaluto's net worth?

The estimated net worth of Michelle LaSpaluto is at least $1.48 million as of February 13th, 2025. Ms. LaSpaluto owns 172,977 shares of Chimerix stock worth more than $1,477,224 as of May 3rd. This net worth approximation does not reflect any other assets that Ms. LaSpaluto may own. Learn More about Michelle LaSpaluto's net worth.

How old is Michelle LaSpaluto?

Ms. LaSpaluto is currently 49 years old. There are 5 older executives and no younger executives at Chimerix. The oldest executive at Chimerix is Dr. Allen S. Melemed M.B.A., M.D., Chief Medical Officer, who is 60 years old. Learn More on Michelle LaSpaluto's age.

How do I contact Michelle LaSpaluto?

The corporate mailing address for Ms. LaSpaluto and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at ir@chimerix.com. Learn More on Michelle LaSpaluto's contact information.

Has Michelle LaSpaluto been buying or selling shares of Chimerix?

Michelle LaSpaluto has not been actively trading shares of Chimerix during the past quarter. Most recently, Michelle Laspaluto sold 2,260 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.51, for a transaction totalling $10,192.60. Following the completion of the sale, the chief financial officer now directly owns 172,977 shares of the company's stock, valued at $780,126.27. Learn More on Michelle LaSpaluto's trading history.

Who are Chimerix's active insiders?

Chimerix's insider roster includes Michael Alrutz (Senior Vice President and General Counsel), Michael Andriole (President, CEO, and Director), Martha Demski (Director), David Jakeman (Insider), Michelle LaSpaluto (Chief Financial Officer), Allen Melemed (Chief Medical Officer), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.

Are insiders buying or selling shares of Chimerix?

In the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 22,045 shares worth more than $92,241.70. The most recent insider tranaction occured on February, 13th when insider Allen S Melemed sold 3,065 shares worth more than $13,792.50. Insiders at Chimerix own 13.1% of the company. Learn More about insider trades at Chimerix.

Information on this page was last updated on 2/13/2025.

Michelle LaSpaluto Insider Trading History at Chimerix

See Full Table

Michelle LaSpaluto Buying and Selling Activity at Chimerix

This chart shows Michelle Laspaluto's buying and selling at Chimerix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Chimerix Company Overview

Chimerix logo
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.54
Low: $8.54
High: $8.54

50 Day Range

MA: $8.15
Low: $4.60
High: $8.55

2 Week Range

Now: $8.54
Low: $0.75
High: $8.55

Volume

N/A

Average Volume

2,317,548 shs

Market Capitalization

$801.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A